Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Insulet Corporation

Capitalization 16.77B 14.4B 13.02B 12.46B 22.76B 1,540B 23.48B 153B 61.4B 739B 62.94B 61.61B 2,644B P/E ratio 2026 *
37.8x
P/E ratio 2027 * 29.7x
Enterprise value 16.67B 14.32B 12.94B 12.39B 22.63B 1,531B 23.34B 152B 61.03B 734B 62.57B 61.24B 2,629B EV / Sales 2026 *
5.05x
EV / Sales 2027 * 4.16x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -
1 day+0.09%
1 week-1.82%
Current month-3.30%
1 month-4.94%
3 months-18.93%
6 months-29.43%
Current year-16.10%
1 week 233.29
Extreme 233.29
243.86
1 month 233.29
Extreme 233.29
275.1
Current year 233.29
Extreme 233.29
299.8
1 year 233.29
Extreme 233.29
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 26.5
Extreme 26.5
354.88
Manager TitleAgeSince
Chief Executive Officer 55 27/04/2025
Director of Finance/CFO 53 29/09/2025
Compliance Officer 50 30/11/2022
Director TitleAgeSince
Chairman 61 31/12/2018
Director/Board Member 61 26/07/2015
Director/Board Member 59 09/08/2017
Change 5d. change 1-year change 3-years change Capi.($)
-0.07%-1.82%-2.80%-21.41% 16.77B
+0.09%-2.26%-16.67%+12.58% 192B
-0.86%-6.77%-4.45%+14.30% 115B
-0.21%-4.44%+34.97%+137.13% 68.51B
+1.20%-1.89%+59.67%+94.98% 58.62B
-0.49%-4.89%-27.48%-29.51% 46.66B
+0.20%-0.23% - - 34.8B
-1.94%-8.94%-5.52%-40.01% 26.09B
-1.17%-9.81%-3.88%+22.74% 21.78B
+0.54%+2.01%-24.00%+14.49% 19.11B
Average -0.22%-4.33%+1.09%+22.81% 59.99B
Weighted average by Cap. -0.13%-4.39%+0.29%+30.12%

Financials

2026 *2027 *
Net sales 3.3B 2.84B 2.56B 2.46B 4.48B 303B 4.63B 30.2B 12.09B 145B 12.4B 12.14B 521B 3.94B 3.38B 3.06B 2.93B 5.34B 362B 5.51B 35.98B 14.41B 173B 14.77B 14.46B 621B
Net income 441M 379M 343M 328M 599M 40.55B 618M 4.04B 1.62B 19.44B 1.66B 1.62B 69.6B 567M 487M 440M 421M 769M 52.06B 794M 5.18B 2.07B 24.96B 2.13B 2.08B 89.36B
Net Debt -98.79M -84.83M -76.68M -73.42M -134M -9.07B -138M -903M -362M -4.35B -371M -363M -15.57B -399M -342M -310M -296M -541M -36.62B -558M -3.65B -1.46B -17.56B -1.5B -1.46B -62.87B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
11/03/26 238.50 $ +0.11% 237,251
10/03/26 238.24 $ -0.89% 832,240
09/03/26 240.38 $ +1.42% 928,165
06/03/26 237.01 $ -1.63% 1,226,675
05/03/26 240.94 $ -0.80% 936,173
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
238.24USD
Average target price
354.40USD
Spread / Average Target
+48.76%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW